Evidence map›Paper›PMID 35845297›Full record

ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2022

A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19.

Dallis Q Ngo, Kewan Hamid, Haris Rana, Maria Cardinale, Douglas Frenia, Nabil Ghani, Henry Redel

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Glucocorticoids and COVID-19.Pharmacological research · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Dallis Q NgoDivision of Pulmonary, Critical Care and Sleep Medicine, Saint Peter's University Hospital, New Brunswick, NJ, USA.ORCID https://orcid.org/0000-0003-3629-0866
Kewan HamidDivision of Pulmonary and Critical Care, University of South Alabama, Mobile, AL, USA.ORCID https://orcid.org/0000-0002-8527-8049
Haris RanaDivision of Pulmonary, Critical Care and Sleep Medicine, Saint Peter's University Hospital, New Brunswick, NJ, USA.ORCID https://orcid.org/0000-0003-0085-1895
Maria CardinaleDivision of Pharmacy, Ernest Mario School of Pharmacy, Rutgers The State University of New Jersey, Piscataway, NJ, USA.ORCID https://orcid.org/0000-0002-7090-8837
Douglas FreniaDivision of Pulmonary, Critical Care and Sleep Medicine, Saint Peter's University Hospital, New Brunswick, NJ, USA.ORCID https://orcid.org/0000-0002-4667-4962
Nabil GhaniDivision of Internal Medicine, Saint Peter's University Hospital, New Brunswick, NJ, USA.
Henry RedelDivision of Infectious Diseases, Saint Peter's University Hospital, New Brunswick, NJ, USA.ORCID https://orcid.org/0000-0002-4816-5168
Saint Peter's University Hospital · USRutgers, The State University of New Jersey · USUniversity of South Alabama · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: RECOVERY, ACTT-1, and ACTT-2 trials have demonstrated that utilization of dexamethasone, remdesivir, or a combination of remdesivir with baricitinib leads to mortality benefit and faster time to recovery, respectively. However, no studies have investigated the benefit of triple therapy of dexamethasone, remdesivir, and baricitinib. We investigate the benefits of triple therapy compared to dual therapy of dexamethasone with remdesivir in patients with severe COVID-19 on HFNC. Materials and Methods: A retrospective data analysis was performed on patients with severe COVID-19 requiring HFNC and evaluated for hospital discharge status, requirement of mechanical ventilation, length of stay, and days on HFNC. Results: Among 191 patients with severe COVID-19, 81 patients received dexamethasone, remdesivir, and baricitinib. Patients receiving triple therapy had a significant survival benefit (HR 0.52; Conclusions: The use of dexamethasone, remdesivir, and baricitinib in patients with severe COVID-19 requiring HFNC was associated with a significant survival benefit in comparison to dual therapy of dexamethasone with remdesivir.

Identifiers

PMID35845297
PMCPMC9279094
OpenAlexW4284881135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.